ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Breast Cancer
Neoplasm Metastasis

Lung Cancer trials near Barcelona, CT, ESP:

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

(PFS) for the treatment of first-line stage IV non-small cell lung cancer (NSCLC) patients, leading to such combinations becoming a...

Enrolling
NSCLC (advanced Non-small Cell Lung Cancer)
Stage IV Lung Cancer
Drug: CIS-DPI

Phase 1, Phase 2

Inhatarget Therapeutics

Barcelona, Spain and 14 other locations

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Barcelona, Spain and 84 other locations

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Zimberelimab

Phase 2

Gilead Sciences
Gilead Sciences

Barcelona, Spain and 50 other locations

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...

Active, not recruiting
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Barcelona, Spain and 38 other locations

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Enrolling
Extensive Stage Small Cell Lung Cancer
Drug: Tarlatamab

Phase 1

Amgen
Amgen

Barcelona, Catalonia, Spain and 30 other locations

Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...

Enrolling
Lung Cancer
EGFR Mutation-Related Tumors
Drug: BG-60366

Phase 1

BeiGene
BeiGene

Barcelona, Spain and 27 other locations

cell vaccine as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC). It is expected that three Spanish sites ...

Active, not recruiting
Extensive-stage Small Cell Lung Cancer
Drug: Atezolizumab 1200 mg in 20 ML Injection
Drug: Carboplatin

Phase 1, Phase 2

Instituto Oncológico Dr Rosell

Barcelona, Spain and 2 other locations

locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...

Active, not recruiting
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Barcelona, Spain and 36 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Barcelona, Spain and 210 other locations

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Barcelona, Spain and 124 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems